secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0000950170-24-115955
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences receives Nasdaq deficiency notices for bid price and stockholders' equity; intends to appeal
--------------------------------------------------------------------------------

- Nasdaq notified REVB of non-compliance with $1.00 minimum bid price rule as of October 16, 2024.
- Company not eligible for 180-day cure period due to reverse stock splits exceeding 250:1 cumulative ratio over two years.
- Also cited for stockholders' equity deficiency (rule 5550(b)(1)), but company believes it satisfied requirement as of Sept 30, 2024 via Q3 financing.
- Company will request a hearing before Nasdaq hearings panel to stay any suspension or delisting pending appeal.
- Trading of common stock (REVB) and warrants (REVBW) continues on Nasdaq Capital Market for now.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024115955/0000950170-24-115955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024115955/revb-20241016.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-115955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer